首页> 美国卫生研究院文献>Human Gene Therapy Methods >Function and Safety of Lentivirus-Mediated Gene Transfer for CSF2RA-Deficiency
【2h】

Function and Safety of Lentivirus-Mediated Gene Transfer for CSF2RA-Deficiency

机译:慢病毒介导的基因转移对CSF2RA缺陷的功能和安全性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hereditary pulmonary alveolar proteinosis (hPAP) is a rare disorder of pulmonary surfactant accumulation and hypoxemic respiratory failure caused by mutations in CSF2RA (encoding the granulocyte/macrophage colony-stimulating factor [GM-CSF] receptor α-chain [CD116]), which results in reduced GM-CSF-dependent pulmonary surfactant clearance by alveolar macrophages. While no pharmacologic therapy currently exists for hPAP, it was recently demonstrated that endotracheal instillation of wild-type or gene-corrected mononuclear phagocytes (pulmonary macrophage transplantation [PMT]) results in a significant and durable therapeutic efficacy in a validated murine model of hPAP. To facilitate the translation of PMT therapy to human hPAP patients, a self-inactivating (SIN) lentiviral vector was generated expressing a codon-optimized human CSF2RA-cDNA driven from an EF1α short promoter (Lv.EFS.CSF2RAcoop), and a series of nonclinical efficacy and safety studies were performed in cultured macrophage cell lines and primary human cells. Studies in cytokine-dependent Ba/F3 cells demonstrated efficient transduction, vector-derived CD116 expression proportional to vector copy number, and GM-CSF-dependent cell survival and proliferation. Using a novel cell line constructed to express a normal GM-CSF receptor β subunit and a dysfunctional α subunit (due to a function-altering CSF2RAG196R mutation) that reflects the macrophage disease phenotype of hPAP patients, it was demonstrated that Lv.EFS.CSF2RAcoop transduction restored GM-CSF receptor function. Further, Lv.EFS.CSF2RAcoop transduction of healthy primary CD34+ cells did not adversely affect cell proliferation or affect the cell differentiation program. Results demonstrate Lv.EFS.CSF2RAcoop reconstituted GM-CSF receptor α expression, restoring GM-CSF signaling in hPAP macrophages, and had no adverse effects in the intended target cells, thus supporting testing of PMT therapy of hPAP in humans.
机译:遗传性肺泡蛋白沉着症(hPAP)是由CSF2RA(编码粒细胞/巨噬细胞集落刺激因子[GM-CSF]受体α-链[CD116])突变引起的罕见的肺表面活性物质积聚和低氧性呼吸衰竭疾病。肺泡巨噬细胞减少GM-CSF依赖性肺表面活性剂清除的作用。尽管目前尚无针对hPAP的药物疗法,但最近证明,气管内滴注野生型或基因校正的单核吞噬细胞(肺巨噬细胞移植[PMT])可在经过验证的hPAP鼠模型中产生显着且持久的治疗效果。为方便PMT疗法向人类hPAP患者的翻译,生成了一种自灭活(SIN)慢​​病毒载体,该载体表达了由EF1α短启动子驱动的密码子优化的人CSF2RA-cDNA(Lv.EFS.CSF2RA coop ),并在培养的巨噬细胞系和原代人细胞中进行了一系列非临床疗效和安全性研究。对细胞因子依赖性Ba / F3细胞的研究表明有效的转导,与载体拷贝数成正比的载体衍生的CD116表达以及GM-CSF依赖性细胞的存活和增殖。使用一种能够表达正常GM-CSF受体β亚基和功能异常的α亚基(由于功能改变的CSF2RA G196R 突变)表达的新型细胞系来反映hPAP患者的巨噬细胞疾病表型,证实了Lv.EFS.CSF2RA coop 转导恢复了GM-CSF受体功能。此外,Lv.EFS.CSF2RA coop 转导健康的原代CD34 + 细胞不会不利地影响细胞增殖或影响细胞分化程序。结果表明,Lv.EFS.CSF2RA coop 重构了GM-CSF受体α表达,恢复了hPAP巨噬细胞中的GM-CSF信号传导,并且对预期的靶细胞无不良影响,从而支持了PMT治疗人类中的hPAP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号